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Abstract
Background: An important step in the proteomics of solid tumors, including breast cancer, consists of
efficiently extracting most of proteins in the tumor specimen. For this purpose, Radio-
Immunoprecipitation Assay (RIPA) buffer is widely employed. RIPA buffer's rapid and highly efficient cell
lysis and good solubilization of a wide range of proteins is further augmented by its compatibility with
protease and phosphatase inhibitors, ability to minimize non-specific protein binding leading to a lower
background in immunoprecipitation, and its suitability for protein quantitation.
Results: In this work, the insoluble matter left after RIPA buffer extraction of proteins from breast tumors
are subjected to another extraction step, using a urea-based buffer. It is shown that RIPA and urea lysis
buffers fractionate breast tissue proteins primarily on the basis of molecular weights. The average
molecular weight of proteins that dissolve exclusively in urea buffer is up to 60% higher than in RIPA.
Gene Ontology (GO) and Directed Acyclic Graphs (DAG) are used to map the collective biological and
biophysical attributes of the RIPA and urea proteomes. The Cellular Component and Molecular Function
annotations reveal protein solubilization preferences of the buffers, especially the compartmentalization
and functional distributions.
It is shown that nearly all extracellular matrix proteins (ECM) in the breast tumors and matched normal
tissues are found, nearly exclusively, in the urea fraction, while they are mostly insoluble in RIPA buffer.
Additionally, it is demonstrated that cytoskeletal and extracellular region proteins are more soluble in urea
than in RIPA, whereas for nuclear, cytoplasmic and mitochondrial proteins, RIPA buffer is preferred.
Extracellular matrix proteins are highly implicated in cancer, including their proteinase-mediated
degradation and remodelling, tumor development, progression, adhesion and metastasis. Thus, if they are
not efficiently extracted by RIPA buffer, important information may be missed in cancer research.
Conclusion: For proteomics of solid tumors, a two-step extraction process is recommended. First,
proteins in the tumor specimen should be extracted with RIPA buffer. Second, the RIPA-insoluble material
should be extracted with the urea-based buffer employed in this work.
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Background
Over the past few years, proteomics has emerged as a pow-
erful new technology, capable of generating unprece-
dented details of protein maps in a wide range of cell types
and disease processes. Increasingly, however, it is becom-
ing recognized that the success of a proteomic experiment
is critically dependent on the sample preparation step. An
ideal sample prep protocol should not only isolate as
much of the proteins of interest as possible from the bio-
logical source, but also preserve optimal sample integrity
and morphology. It should also present the entire sample
in a form that is compatible with optimum mass spectro-
metric analysis.
Proteins in their native states are generally embedded in
their natural environments where they are associated with
other proteins, biological macromolecules or other matrix
materials. They may also be components of multi-protein
complexes, integrated into plasma membranes or
organelles. They are generally insoluble in their native
states once isolation from their biological environments.
They must therefore be denatured in order to bring them
into solution. This ultimately entails dissociating the
chemical bonds connecting them in their native states.
The bonds, and appropriate agents/methods for dissociat-
ing them [1] include: disulfide bond (reduction & alkyla-
tion), hydrogen bond (chaotropes), electrostatic
interactions (salts, charged detergents, chaotropes), charge-
dipole (chaotropes), dipole-dipole (strong dipolar mole-
cules), van der Waals (salt, dipolar molecules, chaotropes),
and hydrophobic interactions (salts, dipolar molecules, cha-
otropes).
Effective sample preparation for proteomics disrupts these
associations, and solubilizes as large a subset of the pro-
teins as possible. Sample solubilization buffers typically
contain a number of additives (chaotropes, detergents,
reducing agents, buffers, salts, and ampholytes). In pro-
teomics, perhaps two of the most effective and widely
employed lysis buffers for extracting proteins from cells
and tissues are Radio-Immunoprecipitation Assay buffer
(RIPA buffer) [2] and urea lysis buffer [1,3,4].
The base ingredients of a typical RIPA buffer include: 50
mM Tris HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate and 0.1% SDS. Protease and phos-
phatase inhibitors are additionally added prior to use,
depending on the application (these are usually not
added when preparing lysates for phosphatase assays).
Additional optimization of the lysis procedure, or substi-
tution of the base ingredients may be required for each
specific application, for example PBS pH 7.4 can substi-
tute for both Tris HCl and NaCl. An example variant of
RIPA buffer that contains protease and phosphatase
inhibitors consists of: 10 mM Tris, pH 7.4, 100 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2
mM Na3VO4, 0.1% SDS, 0.5% sodium deoxycholate, 1%
Triton-X 100, 10% glycerol, 1 mM PMSF (made from a 0.3
M stock in DMSO) or 1 mM AEBSF (water soluble version
of PMSF), 60 μg/mL aprotinin, 10 μg/mL leupeptin, 1 μg/
mL pepstatin (alternatively, protease inhibitor cocktail
may be used).
RIPA buffer's rapid and efficient cell lysis and solubiliza-
tion of a wide range of proteins, including cytoplasmic,
membrane and nuclear proteins, makes it a standard for
Western blotting. Its versatility is further augmented by its
compatibility with protease and phosphatase inhibitors,
stability, and ability to minimize non-specific protein-
binding interactions leading to low backgrounds in
immunoprecipitation. Still, RIPA buffer is very compati-
ble with a myriad of applications, including reporter
assays, protein assays, immunoassays and protein purifi-
cation. When protein quantitation is desired, RIPA buffer
is the lysis buffer of choice due to its compatibility with
the BCA Protein Assay, although it can denature kinases
[5], and can disrupt protein-protein interactions in immu-
noprecipitation/pull down assays [6].
Urea buffer is another versatile and efficient cell and tissue
lysing buffer whose typical composition include: TRIS
base 40 mM, Urea 7 M, Thiourea 2 M, NP-40 or CHAPS
4%, DTT 10 mM. Urea is used at concentrations ranging
from 5 to 9 M, often with thiourea at concentrations up to
2 M. The additive thiourea can dramatically enhance the
solubility of a wide range of proteins – nuclear, mem-
brane, cytosolic, and including even tubulin that is highly
prone to aggregation, in urea buffer [1,3,4]. As in RIPA
buffer, different detergents and buffers can be substituted
for the buffering base, NP-40 or CHAPS, depending on
the application. Urea inactivates proteases that degrade
cellular proteins [7]. Therefore, there is little need to add
protease inhibitors. However, urea and thiourea can
hydrolyze to cyanate and thiocyanate, respectively, which
can modify amino groups on proteins, (e.g. carbamyla-
tion of proteins by isocyanate), and this hydrolysis is pro-
moted by heat.
Extracellular matrix (ECM) proteins (collagens, fibronec-
tin, vitronectin, thrombospondin, laminins, tenascin,
osteopontin and entatin, etc.) are highly implicated in
tumor cell growth, motility, angiogenesis, apoptosis, pro-
liferation, invasion and metastasis [8-22]. They contribute
to signal transduction, differentiation, site-specific gene
expression, immunological functions, wound healing and
inflammation [8,15,17,18,22,23]. They and their remod-
eling enzymes, including urokinase plasmogen activators,
matrix metalloproteinases and cathepsins L, B and D, are
also known to profoundly modulate mammary gland
branching morphogenesis [24]. They are also importantProteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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biomarkers of breast cancer. For example, Veeck and co-
workers [9] showed recently that the extracellular matrix
protein Inter-α-trypsin inhibitor is strongly down-regu-
lated in all human breast cancers.
Thus, in cancer proteomics, especially where it is desired
to recover as much of the cellular or tissue proteins as pos-
sible, it is important not to completely rely on a single
lysis buffer that could exclude an entire class of critically
needed proteins, especially the low abundance proteins.
Indeed, there are numerous proteomics publications that
fall exactly under the above category. In breast cancer pro-
teomics, for example, articles are found (example Refs
[23,25-30]) wherein researchers wanted to extract all pro-
teins present in the breast tumor specimens, but used
RIPA buffer as the sole buffer.
In a study of ECM components in differentiating terato-
carcinoma cells, Grover and Adamson [31] noted that
fibronectin was poorly solubilized in RIPA buffer. Other-
wise, no other direct reference suggesting insolubility of
ECMs in RIPA buffer was found as yet. Instead, researchers
(examples: Refs [9,13-15,20,32]), routinely use RIPA
buffer as the sole lysis and solubilization buffer in the
immunoprecipitation [15], immunoblot [13,14,20] and
Western blot [9,32] analysis of extracellular matrix pro-
teins.
Methods
The key steps (Figure 1) include protein extraction from
breast tumors and matched normal breast tissues, sample
clean-up with GE Healthcare tools, trypsin digestion,
desalting with Michrom cartridges, mass spectrometry/2D
nano-LC/ESI-MS/MS, database search and protein ID,
data processing and bioinformatics.
Breast tumor tissue lysates
Protein lysates of breast tumors and matching normal
breast tissues are obtained from Protein Biotechnologies,
Inc. (Ramona, CA). The samples are selected to represent
different types of tumors (T2-018 Tumor, T2-048 Tumor,
T2-029 Tumor), non-neoplastic normal breast tissue (T2-
048 Normal), Diagnosis, Stage, Grade, Age and Gross
Findings (Table 1).
Protein extraction
Lysates provided by Protein Biotechnologies were
extracted by a two-step procedure. First, proteins are
extracted with a modified Radio-Immunoprecipitation
Assay (RIPA) lysis buffer to yield the soluble fraction. Sec-
Proteomics Workflow: flow chart Figure 1
Proteomics Workflow: flow chartoutlining the key experimental steps in this work.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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ond, the residual insoluble fraction left after RIPA buffer
extraction is subjected to additional extraction using a
urea-based buffer to produce a second protein fraction.
The compositions of the lysis buffers are as follows:
Extraction 1
Radioimmunoprecipitation Assay Lysis Buffer (modi-
fied). Base Ingredients (PBS, pH 7.4, SDS, 0.1%, Na-deox-
ycholate, 0.25%); RIPA Protease Inhibitors (1 mM,
Phenylmethylsulfonyl fluoride (PMSF), EDTA, 1 mM (cal-
cium chelator; 100 mM stock solution in H2O, pH 7.4),
Leupeptin, 1 μg/mL, Aprotinin, 1 μg/mL, Pepstatin, 1 μg/
mL, NaF (1 mM),); RIPA Phosphatase Inhibitors (Acti-
vated Na3VO4 (1 mM)).
Extraction 2
Urea Lysis Buffer (PBS, pH 7.4, 5.0 M Urea, 2.0 M Thiou-
rea, 50 mM DTT, 0.1% SDS).
Cleanup of lysates
In the cleanup step, the proteins are separated from buff-
ers, detergents, salts and other contaminants, using a
method that is largely derived from a protocol and 2D
clean-up kit provided by Amersham Biosciences (GE
Healthcare, Piscataway, NJ). The kit consists of four rea-
gents: a precipitant that precipitates the proteins to form
pellets, a co-precipitant that co-precipitates with the pro-
teins and enhances their removal from solution, a wash
buffer that removes non-protein contaminants from the
protein precipitate, and a wash additive that promotes
rapid and complete re-suspension of the sample proteins.
Prior to the beginning of clean-up, the wash buffer was
chilled at -20°C for 1 hr. After thawing and spinning
down 100 μg aliquots of breast tumor lysates and
matched normal breast tissue lysates, 300 μL of the pre-
cipitant was added. The mixture was vortexed on Eppen-
dorf Thermomixer R (Eppendorf North America,
Westbury, NY), and then incubated in ice for 15 minutes.
Next, 300 μL of co-precipitant was added and the mixture
mixed. The mixture was centrifuged at 12000 × g for 5
minutes to pellet the proteins. The clear supernatant liq-
uid was carefully pipetted out while retaining the protein
precipitate at the bottom of the 1.5 mL Eppendorf tube.
Without disturbing the pellet layer, 40 μL of co-precipi-
tant was added to the supernatant, through the tilted side
of the 1.5 mL Eppendorf tube. The mixture was kept in ice
for 5 minutes before centrifuging it again at 12000 × g for
another 5 minutes. The pellet was dispersed by adding 25
μL of MilliQ water and centrifuging for 10 minutes. After
adding 1 mL of chilled wash buffer at -20°C and 5 μL of
wash additive, the mixture was vortexed once every 30 sec-
onds for a total of 35 minutes. At this point, the proteins
did not dissolve, but dispersed. The mixture was again
centrifuged at 12000 × g for 5 minutes. The supernatant
was carefully discarded, and the pellet dried. The pellets
are amorphous.
In-solution digestion
The dried pellet was re-suspended in 20 μL 8 M urea/100
mM ammonium bicarbonate (ABC), and 0.6 μL of 100
mM Dithiothreitol (DTT) in 100 mM ABC (i.e. 3 mM
DTT) was stirred in Eppendorf Thermomixer R (Eppen-
dorf North America, Westbury, NY) for 1 hr at 29°C. After
adjusting to room temperature, 1.5 μL of 200 mM iodoa-
cetamide (IAA) in 100 mM ABC (final concentration of 15
mM IAA) was added. Alkylation was then carried out by
incubating the mixture for 45 minutes in a darkroom.
Table 1: Characteristics of the breast tumors and matched normal breast tissues analyzed in this work.
T2-018 Tumor T2-048 Tumor T2-048 Normal T2-029 Tumor
Location Right breast Left breast Left breast Bilateral
Diagnosis Infiltrating ductal carcinoma Infiltrating ductal carcinoma Normal Adenocarcinoma
Stage IV T4N0M0 IIB T2N1M0 Normal IV T4N1M0
Grade II I I III
Sex Female Female Female Female
Age 75 years 39 years 39 years 47 years
Gross Findings Tumor size: 8 × 8 cm., ill 
demarcated. Cut section firm
Tumor size: 3 × 3.5 cm. ill 
demarcated. Cut section soft 
and white.
Tissue size: 3 × 3.5 cm. Tumor size 2 × 2 cm., and 3 × 2 
cm., ill demarcated. Cut section 
firm and gray/white
Source: Integrated Laboratory Services-Biotech (ILSbio), Chestertown, MD 21620. http://www.ilsbio.com ILS-19106.
Detailed histopathology reports are available at the Protein BioTechnologies website : http://www.proteinbiotechnologies.com/Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
Page 5 of 24
(page number not for citation purposes)
Then, 1.5 μL of 200 mM DTT/100 mM ABC was added to
consume any un-reacted IAA. The urea concentration was
reduced to about 1 M by diluting the mixture with 140 μL
of (50 mM ABC + 2 mM CaCl2). Digestion was carried out
by adding 6 μL of 0.40 μg/μL = 2.4 μg of Promega
Sequencing Grade trypsin and incubating in Eppendorf
Thermomixer R for 20 hr at 37.4°C.
At the end of the 20-hr incubation, reaction was stopped
by adding 4.0 μL of 2% acetonitrile. Then, 6 μL of 10%
TFA was added to adjust the pH to 5.0.
Desalting
Manual, Micro trap desalting cartridge and protocol from
Michrom (Michrom BioResources, Auburn, CA) are used.
First, the micro Trap is washed with 80 μL of LCMS Sol-
vent B (90%ACN/0.1% TFA). Next, it is equilibrated with
80 μL of LCMS Solvent A (2% ACN/0.1% TFA). Then, 20
μL of peptide digest sample is loaded onto the micro Trap;
salts are removed by washing with 50 μL aliquots of LCMS
solvent A (2% ACN/0.1% TFA). Tryptic peptides are
eluted from the micro Trap with 16 μL of 70% ACN.
Desalted peptides are evaporated to dryness on an SC2
SpeedVAC® Plus Thermo savant (Thermo Fisher Scientific,
Waltham, MA).
Multidimensional nanoHPLC
The nano-HPLC is a Paradigm MS4B Multi-Dimensional
HPLC equipped with a Michrom Paradigm AS1 refriger-
ated autosampler and χCalibur software plugin (Michrom
BioResources, Auburn, CA). It is configured and operated
in a 3-1 column-switching arrangement. All four pumps
are used; pump D is used for sample loading onto captrap
cartridge (sample concentration and de-salting) at 50 μL/
minute for 5 minutes. Solvents A is 100% MilliQ water,
no additives added. Solvent B is HPLC Grade acetonitrile
(ACN) from Burdick and Jackson (Honeywell Burdick &
Jackson, Morristown, NJ), no additives added. Solvent C
is 100 mL of FA/HFBA mix + 900 mL water; (FA = formic
acid, HFBA = HPLC Grade Ionate™ Heptafluorobutyric
acid from Pierce (Pierce Biotechnologies, Rockford, IL)).
The FA/HFBA mix consists of 10% FA + 0.5% HFBA +
89.5% water. Solvent D is made by mixing 10 mL FA/
HFBA mix + 20 mL ACN + 970 mL water.
The stock solution used to make up the MudPIT salt solu-
tions is prepared as follows: 5% ACN + 90% water + 2.5%
formic acid + 2.5% ammonium hydroxide + 0.05% HFBA.
The salt plugs for MudPIT analysis are then prepared by
serial dilution of this stock solution with solvent D
described above.
An optimized 60-minute nano gradient consists of the fol-
lowing settings:
Time (min), Flow rate (μl/min), B (%), C (%) :: (0.00, 0.30,
5.00, 10.00 :: 5.00, 0.30, 5.00, 10.00 :: 12.00, 0.30, 15.00,
10.00 :: 47.00, 0.30, 40.00, 10.00 :: 55.00, 0.30, 60.00,
10.00 :: 56.00, 0.30, 80.00, 10.00 :: 58.00, 0.30, 80.00,
10.00 :: 59.00, 0.30, 5.00, 10.00 :: 65.00, 0.30, 5.00,
10.00).
The five Solvent System and Event Group 2(D2) pulse
sequences for autosampler, mass spec and solvent flow as
follows: Time (min), Event :: (0.00, Valve 1 inject :: 0.05,
Valve 2 inject :: 5.00, Valve 2 Load :: 5.10, Start Mass Spec
:: 0.00, Valve 1 inject), whereas three Solvent System and
Event Group 1(D1) settings for sample concentration and
desalting on trap column are: Time (min), flow (μL/min) ::
(0.00, 50 :: 5.00, 50 :: 5.10, 5.00).
Columns (Michrom BioResources)
￿ Peptide Nanotrap (TR5/25109/42): 150 μm × 50 mm;
400 nL volume.
￿ Nanotrap analytical column (CL5/61241/00): 5 μm 200
Magic C18 75 μm × 150 mm.
￿ SCX Captrap (TR1/25108/35): Contains a medium
pore, large particle, silica-based strong cation exchange
material (PolySulfoethyl Aspartamide). Binds protein
digests, peptides, and other molecules (0.5–50 kD) for 1D
or 2D analysis. Concentrates samples up to 100 fold (pH
range 2.7–7.0).
Nano-LC/MS/MS
One-dimensional (1D) and two-dimensional (2D) nano
HPLC experiments are run at a flow rate of 300 nL/min.
Samples are loaded onto trap columns for concentration
and desalting at 50 μL/min. For each experiment, 12 μL of
peptide digest resulting from 50–100 μg total protein is
used: 2 μL is injected for 1D; 10 μL for 2D. Each shotgun
experiment consists of a 12-cycle MudPIT run in which a
60-minute nano-LC gradient is run for each of: 1D, 2D,
2D (0 mM NH4COO), 2D (25 mM NH4COO), 2D (50
mM NH4COO), 2D (75 mM NH4COO), 2D (100 mM
NH4COO), 2D (150 mM NH4COO), 2D (200 mM
NH4COO), 2D (250 mM NH4COO), 2D (300 mM
NH4COO) and 2D (500 mM NH4COO).
Nanospray
The nanospray is a Paradigm Nanotrap Platform
(Michrom BioResources, Auburn, CA) equipped with a
Paradigm Metal spray needle. The spray tip is a 7.5 cm
long, 30 μm (Internal Diameter) × 105μm (Outer Diame-
ter) surgical stainless steel, electrochemically cut and pol-
ished, and sheathed by a 125 μm PEEK Tubing. The
needle permits flow range of 0.5 to 10 μL/min and a volt-
age range of 1000 to 5000 Volts. A 1/16" stainless steel
Valco nut attaches the spray needle to a 1/16" to 1/16"Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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Valco union, which is mounted on the Nanotrap Plat-
form.
Nanospray source parameters
Sheath Gas Flow Rate = 0; Aux Gas Flow Rate = 0; Spray
Voltage (kC) = 2.51; Spray Current (μA) = -0.05; Capillary
Temp (°C) = 221.10; Capillary Voltage (V) = 9.22; Tube
Lens Offset (V) = 50.
Mass spectrometry
Data-dependent MS and MS/MS spectra are acquired on
an LCQ Deca Xp plus (Thermo Fisher Scientific, San Jose,
CA).
MS and MS/MS
Five scan events are recorded for each data acquisition
cycle. The first scan event is used for full scan MS acquisi-
tion from 300–1800 m/z. Data are recorded in the cen-
troid mode only (scan event #1 does not permit profile
mode of data acquisition). The remaining four scan events
are used for Collisionally Activated Decomposition
(CAD): the four most abundant ions in each MS are
selected and fragmented to produce product ion mass
spectra. All CAD product ions are recorded in the profile
mode.
Ion optics settings used
Multipole 1 Offset (V) = -6.15; Lens voltage (V) = -24.23;
Multipole 2 Offset (V) = -10.54; Multipole RF Amplitude
(Vp-p): = 400; Entrance Lens (V) = -50.79.
MS/MS parameters
Number of microscans: 4; Maximum Injection Time (ms):
200; Isolation width (m/z): 3; Normalized Collision
Energy (%): 35; Activation Q: 0.250; Activation Time
(msec): 30.00; Scan Range: 300–1800 m/z.
Database searches and protein identification
Proteins are identified by searching the MS and MS/MS
spectra against NCBI nr human fasta, using Bioworks v3.2
(Thermo Fisher Scientific, Inc., San Jose, CA). The Unified
Search Results File format (.SRF) is employed, rather than
the traditional SEQUEST *.DTA and *.OUT formats. Pep-
tide and protein hits are scored and ranked using the new
probability-based scoring algorithm and the new final
Score (Sf) that are incorporated in Bioworks 3.2. Because
MS/MS spectra are acquired in the profile mode, each
nano-LC/MS/MS run range in size from 95–120 Mega-
bytes, depending on the number of microscans (typically
4 ms) in the Advanced Define Scan function in the MS/MS
LCQtune file of the Instrument Method.
Filters
Only peptides identified as possessing fully tryptic termini
(containing up to two missed internal trypsin cleavage
sites), with cross-correlation scores (Xcorr) greater than 1.9
for singly charged peptides, 2.3 for doubly charged pep-
tides and 3.75 for triply charged peptides, are used for
peptide identification. In addition, the delta-correlation
scores (ΔCn) must be greater than 0.1 for peptide identifi-
cation. Protein probability P(pro) ≤ 0.001.
Bioinformatics
Bioinformatics calculations are carried out using
Blast2GO [33] Version 1.2.7 http://
web3.vs160142.vserver.de/, a java webstart-enabled Gene
Ontology annotation, visualization and analysis software.
The calculations, as implemented here, consist of three
key sequential steps: (a) Basic Local Alignment Search
Tool (BLAST) [34,35], (b) Mapping and (c) Annotation.
BLAST
In BLAST [34], protein input queries are submitted to the
BLAST server at the National Center for Biotechnology
Information (NCBI) of the National Institutes of Health
(NIH) over the internet http://www.ncbi.nlm.nih.gov/
blast/Blast.cgi. The BLAST server generates hits (hit gene
ids (gi) and gene names/accessions). The input parame-
ters used are as follows: BLAST database, NCBI nr; number
of BLAST hits requested for each query, 40; BLAST expect-
Value (i.e. eValue), 1e-3; BLAST program, blastp; Blast Ver-
sions: BLASTP 2.2.13 [Nov-27-2005] and BLASTP 2.2.15
[Oct-15-2006]; Blast Mode: QBlast-NCBI; HSP length cut-
off: 33 (please see "The NCBI Handbook"[36] for more
information on BLAST parameters).
The blast server accepts only fasta-formatted protein
sequences as input queries. Although Bioworks 3.2 or
later can convert protein sequences into fasta text files, the
protein sequences must be submitted from within Biow-
orks browser prior to exiting the initial protein identifica-
tion step. Thus, batch conversion of protein queries, post-
Bioworks, is not possible via Bioworks route. For example,
Bioworks would not allow the analysis of only the pro-
teins that occur in both tumor and normal, because these
must be determined post-Bioworks protein identification.
Another approach is Batch Entrez at the NCBI website
http://www.ncbi.nlm.nih.gov/entrez/batchent
rez.cgi?db=Nucleotide), with *Protein database* selected
to import the batch file and displaying all in fasta format.
For each of the protein input queries, the BLAST machine
generates a BLAST Table [34], exemplified here (Addi-
tional File 1) with discoidin domain receptor 1 (DDR1):
gi|68533097|dbj|BAE06103.1|/894 (DDR1 is found in
T2-081-T1, T2-018T2, T2-029-T2, T2-048N1, and T2-
048N2 (Table 1)). The BLAST Table shows parameters of
the BLAST search: Sequences producing significant align-
ments, Gene Name, Accession number, e-Value, align-Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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length, positives, similarity %, hsp and mapping (Ontol-
ogies found), for each of the 40 hits requested.
Mapping
In the Mapping step, various databases are searched to
identify and fetch Gene Ontologies (GO) associated with
the hits obtained from NCBI BLAST searches.
Annotation
The annotation procedure selects the GO terms from the
GO pool obtained by the mapping step and assigning
them to the query sequences, using Annotation Rule.
Annotation parameters are: Pre-eValue-Hit-Filter, 6; Pre-
Similarity-Hit-Filter, 30; Annotation Cut-Off, 55; GO-
Weight, 5.
Annotations are validated and expanded using an annota-
tion expander. The expander, developed by a group at the
Norwegian University of Science and Technology http://
www.goat.no, deploys an additional Gene Ontology
structure: the Second Gene Ontology Layer, to suggest
new Biological Processes and Cellular Components,
based on the gene's existing Molecular Function annota-
tions.
Results
The multidimensional protein identification technology
(MudPIT) mass spectra of the breast specimens T2-018
Tumor, T2-048 Tumor, T2-048 Normal and  T2-029
Tumor, are shown in Additional Files 2, 3, 4 and 5, respec-
tively. The set of 12-cycle spectra to the left of the figures
are the RIPA buffer fractions, whereas the spectra of the 12
urea buffer fractions are shown at right.
The mass spectra clearly show that, for each of the 60-
minute MudPIT runs, the 1D_2 μL and 2D_10 μL spectra
appear to produce higher ion currents than the rest of the
spectra. This may be partly due to the greater concentra-
tions of peptides in these runs: in the 1D_2 μL run, all two
2 μL of approximately 5 μg total peptide digest are intro-
duced into the nano-LC/ESI-MS/MS system via the pep-
tide Nanotrap and analytical column (the SCX column is
bypassed for 1D analysis). And, in 2D_10 μL, all 10 μL of
peptide digest are deposited on the SCX column; all
unbound peptides are washed into the mass spectrometer,
after pre-concentration and de-salting at the 150 μm × 50
mm peptide (40 nanoliter volume) nanotrap. Thus, the
amounts of sample introduced into the mass spectrome-
ter in these two runs maybe responsible for the higher ion
currents.
The MudPIT spectra also show that the RIPA-insoluble
materials contain quite a significant amount of proteins,
as reflected in the highly abundant spectra of urea-soluble
proteins. This clearly raises concern about using RIPA
buffer as the sole lysis buffer for the proteomics of breast
cancer (or other cancers as well).
The proteins identified in the database search of the Mud-
PIT mass spectra are shown in Table 2. Here, T2-048T
Table 2: Proteins found in the MudPIT proteomics of the RIPA and urea fractions of the breast tumors analyzed in this work.
# Proteins # Proteins_validated
Lysate Default • Xcorr (1,2,3): 1.90, 2.3, 3.75
￿ P(pro) : 0.001
 ￿ ΔCn ≥ 0.1
Specimen RIPA Buffer Urea Buffer
T2-018_Tumor * 33147 299
T2-018_Tumor * 31828 155
T2-048_Tumor * 27049 143
T2-048_Tumor * 31329 261
T2-048_Tumor * 28203 195
T2-048_Tumor * 30816 122
T2-029_Tumor * 27944 215
T2-029_Tumor * 24963 358Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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(RIPA) and T2-048N2 (UREA) represent the RIPA-solu-
ble fraction of the tumor sample T2-048 and the urea-sol-
uble fraction of the normal breast tissue sample T2-048,
respectively. The column labelled "Default" depicts the
default number of proteins found by Bioworks 3.2 prior
to application of filter functions and protein validation.
The final sets of proteins identified are shown at the right-
most column. Again, it is clear that the RIPA-insoluble
materials, which dissolve in urea, contain significant
amounts of proteins that would otherwise be discarded if
RIPA buffer was the only lysis and solubilization buffer
used.
The partitioning of the proteins between RIPA and urea
buffers in the infiltrating Ductal Carcinoma case T2-018
TUMOR (Figure 2A) shows that the average molecular
weight of the 217 proteins that dissolve exclusively in
RIPA buffer was 61604 m/z, whereas the 73 proteins that
dissolve exclusively in urea buffer have an average molec-
ular weight of 99154 m/z. That is, the average molecular
weight of proteins that dissolve exclusively in urea was
37551 m/z, or 61% higher than in RIPA buffer. Finally, the
average molecular weight of the 82 proteins that dissolve
in both RIPA and urea buffers was 40490 m/z.
The corresponding data for T2-048 TUMOR, T2-048
NORMAL and T2-029 TUMOR are shown in Venn Dia-
grams in Figures 2B, C and 2D.
Gene Ontology
In an effort to determine the protein groups, and identify
the fractionated proteins contained in the compartments
shown in Table 2 and Figure 2, Gene Ontology
[37,38]http://www.geneontology.org/ was employed.
The Gene Ontology (GO) project, which began in 1998 as
a collaboration between three databases FlyBase, Saccha-
romyces  Genome Database and the Mouse Genome
Database, has today grown to encompass nearly all major
databases, and has become a new powerful tool for min-
ing biology data. Gene Ontology annotates biological
data in terms of their Biological Process, Molecular
Function and Cellular Component.
Biological Process is an ensemble of biochemical trans-
formations that are accomplished by one or more ordered
assemblies of molecular functions. Biological Process may
be broad (physiological process, metabolism, etc) or spe-
cific (nitric oxide metabolism, oxygen transport, etc).
Molecular Function is the specific, elemental action or
task performed by a gene product or assembled complexes
of gene products. Examples of broad molecular functions
include catalysis, binding, and structural molecular activ-
ity, whereas specific molecular functions are exemplified
by tetrapyrrole binding, adenylate cyclase activity and cal-
modulin binding.
Cellular Component is the subcellular location
(organelle, nucleus, etc) and macromolecular complexes
were the gene product is located.
In this work, proteins identified by proteomic analyses are
submitted to GO analyses, including NCBI BLAST, map-
ping and annotation. The results are presented as a
Directed Acyclic Graph (DAG), which shows the number
of annotated sequences and the annotation scores con-
tributing to each node. The nodes are color-coded, and
the relative importance of each annotation score is indi-
cated by the intensity of the orange color at that node.
There are three types of nodes: a double-edged octagon
represents an annotated GO term; a rectangle represents a
non-annotated GO term node, and an oval shape denotes
Gene Ontology obtained by mapping which can directly
be directly associated to one or more BLAST hits.
In the Biological Process formulation, functionalities that
directly identify the proteins in the RIPA and urea buffer
fractions are not explicitly evident. The Molecular Func-
tion annotations, and especially, the Cellular Compo-
nent, however, do provide highly useful information on
protein groups and identities of the protein fractions,
shown in the Venn diagrams of Figure 2. In the following
sections, the Cellular Component annotations will be pri-
marily used to characterize the protein fractions,
although, the Molecular Functions annotations will also
be used.
Cellular Component
T2-018T (RIPA) and T2-018T (Urea) fractions
The Cellular Component DAGs for specimens T2-018T
(RIPA) and T2-018T (Urea) are shown in Figures 3 and 4,
respectively. Interestingly, the Cellular Component parent
node of T2-018T DAG shows that mapping found curated
Gene Ontologies (Ontologies) for 262 out of the original
299 proteins found in this sample (Table 2). Similarly, in
T2-018T, 131 out of the 155 proteins have Ontologies
available in the Go databases. The high percentages of
proteins that have curated Ontologies thus provide ade-
quate bioinformatics data needed to characterize the RIPA
and urea proteomes with high degree of specificity and
reliability.
Comparison of the T2-018T (RIPA) and T2-018T (Urea)
DAGs shows that the entire set of extracellular matrix pro-
tein nodes in the urea (T2-018T; Figure 4) DAG are almost
completely missing from the RIPA (T2-018T; Figure 3)
DAG, at the indicated node filter settings, suggesting that
nearly all extracellular matrix proteins are dissolved in the
urea, but not in the RIPA buffer.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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(A-D): A: The partitioning of the proteins between RIPA and urea buffers in the infiltrating Ductal Carcinoma case T2-018T  (TUMOR) Figure 2
(A-D): A: The partitioning of the proteins between RIPA and urea buffers in the infiltrating Ductal Carcinoma 
case T2-018T (TUMOR). Venn diagram showing that RIPA and urea lysis buffers fractionate breast tumor proteins primarily 
on the basis of molecular weights. The average molecular weight of the 217 proteins that dissolve exclusively in RIPA buffer is 
61604 m/z, whereas the 73 proteins that dissolve exclusively in urea buffer have an average molecular weight of 99154 m/z. B: 
Differential partitioning of proteins extracted from the T2-048 TUMOR between RIPA and urea buffers. Venn diagram showing 
that RIPA and urea lysis buffers fractionate breast tumor proteins on the basis of molecular weights. The average molecular 
weight of the 69 proteins that dissolve almost exclusively in RIPA buffer is 72330 m/z, whereas the 187 proteins that dissolve 
exclusively in urea buffer have an average molecular weight of 79704 m/z. Seventy-four proteins, whose average molecular 
weight is 47854m/z, dissolve fully in both RIPA and urea buffers. C: Matched normal breast tissue T2-048 NORMAL between 
RIPA and UREA buffers. The average molecular weight of the 128 proteins that are soluble nearly exclusively in RIPA buffer is 
61879 m/z, whereas the 55 proteins that dissolve exclusively in urea buffer have an average molecular weight of 93810 m/z. 
Sixty-seven proteins with an average molecular weight of 53102m/z are fully soluble in both RIPA and urea buffers. D: Bilateral 
Adenocarcinoma case T2-029 TUMOR. The average molecular weight of the 104 proteins that dissolve almost exclusively in 
RIPA buffer is 51485 m/z, whereas the 247 proteins that dissolve exclusively in urea buffer have an average molecular weight of 
76092 m/z. One hundred and eleven proteins with an average molecular weight of 45126 m/z are fully soluble in both RIPA and 
urea buffers.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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The node filter is a mechanism of simplifying otherwise
complicated DAGs. At a node filter of 28, for example, all
nodes whose number of annotated protein sequences are
28 or below, are not displayed, n an effort to simplify the
DAG. Thus, when the node filter is lowered, previously
hidden nodes are displayed, making the chart more
crowded.
Close-up sections of the extracellular regions (Figure 5)
clearly show that extracellular matrix proteins dissolve
almost exclusively in urea buffer. The cropped sections are
obtained with node filters of 15 and 10, for the RIPA and
urea DAGs, respectively.
Interestingly, lowering the DAG node filter for the RIPA
DAG did not produce appreciable change in the number
of nodes displayed within the extracellular region shown
in Figure 3, whereas, even a slight lowering of the node fil-
ter in the urea DAG (Figure 4) reveals a large number of
previously hidden nodes, shown here in Figure 6, when
the urea node filter is reduced to zero. Again, this is a fur-
ther confirmation that most of the extracellular matrix
proteins are dissolved in the urea buffer.
Comparison also shows that, for extracellular region,
RIPA buffer has a greater number of annotated protein
sequences and annotation score than Urea buffer: [RIPA:
(extracellular region, Seqs:62 Score:40.87) :: UREA: (extra-
cellular region, Seqs:45 Score:36.31)]. However, this
greater enrichment at the RIPA buffer node may indeed be
due to the greater number of proteins at the RIPA buffer
Cellular Component parent node: [RIPA buffer: (Cellular
Component, Seqs:262 Score:118.5) :: UREA buffer: (Cel-
lular Component, Seqs:131 Score:62.59)]. To correct for
this, and allow for sequence-independent comparison of
the nodes, regardless of the number of protein sequences
that was submitted to GO analyses (Table 2), the
sequences and scores are expressed as percentages of the
sequences and scores present at the Cellular Component
parent node. This process is known as normalization.
Thus, comparison of the extracellular regions become:
[RIPA: (extracellular region, (Seqs:23.7 Score:34.5)) ::
UREA: (extracellular region, (Seqs:34.4 Score:58.0))]. It
can now be stated that, based on Seqs, the extracellular
region is preferentially enriched in Urea buffer by 34.4%,
when compared to RIPA buffer (23.7%). Similar calcula-
tions are shown below, for Seqs of (RIPA/UREA), respec-
tively: nuclear (29.8/20.6), membrane (21.8/21.4),
intracellular (82.4/70.2), protein complex (42.4/34.4),
organelle (66.0/54.2), cytoskeleton (18.7/25.2) and cyto-
plasmic proteins (60.7/48.1). From here, it is clear that
cytoskeletal and extracellular region proteins are selec-
tively enriched in urea buffer, whereas nuclear, intracellu-
lar, protein complexes, organelle, cytoplasmic and
The Cellular Component DAG for the proteome T2-018T (RIPA) Figure 3
The Cellular Component DAG for the proteome T2-018T (RIPA). Extracellular matrix proteins are not observed, 
even at a node filter setting of 28.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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mitochondrial proteins are preferentially enriched in the
RIPA fractions.
Selective protein enrichment comparisons based on both
Seqs and Scores are shown in Figures 7 and 8.
T2-048T (RIPA) and T2-048T (Urea) fractions
Rather than show the entire DAGs, cropped views of the
extracellular regions of T2-048T (RIPA) and T2-048T
(Urea) DAGs (Figure 9) show that extracellular matrix
proteins are present almost exclusively in the urea frac-
tion. It is also seen that mapping found that nearly 90%
of the original proteins present in the T2-048T proteome
(i.e. 232 of 261, Table 2) have existing Ontologies, thus
providing the requisite bioinformatics information
needed for the characterization of the proteins. Similarly,
Ontologies are found for 120 of the 143 proteins (84%)
of the T2-048T proteome.
T2-048N1 (RIPA) and T2-048N2 (Urea) fractions
Here again, the extracellular regions of T2-048N1 (RIPA)
and T2-048N2 (Urea) DAGs (Figure 10) show that extra-
cellular matrix proteins are present nearly exclusively in
urea buffer, with 86% and 80% of the proteins of T2-
048N1  and  T2-048N2 proteomes, respectively, being
found to have existing Ontologies available. It is interest-
ing to compare the normalized extracellular matrix Seqs
and scores of T2-048T (Tumor) and T2-048N2 (Normal):
[T2-048T-UREA: (extracellular matrix (Seqs:13.36
Score:16.80)) :: T2-048N2-UREA: (extracellular matrix,
(Seqs:29.59 Score:32.66))]. The normalized scores and
Seqs belonging to normal breast tissues are more than two
times those of the breast tumors, which may be due to the
degradation of extracellular matrix proteins in the tumor
by proteases to pave the way for the metastasis of cancer
cells [8-22].
T2-029T1 (RIPA) and T2-029T2 (Urea) fractions
The cropped-out extracellular regions, displayed side-by-
side (Figure 11), again show that extracellular matrix pro-
teins are found nearly exclusively in urea buffer. And,
mapping found Ontologies for 84% and 87% of the T2-
029T1 and T2-029T2 proteins, respectively. Upon lower-
ing the node filter on the T2-029T2 DAG to zero, a full
display of the extracellular matrix proteins are obtained
(Additional File 6). Similar lowering of the node filter on
the T2-029T1 DAG did not reveal significantly new or rel-
evant structural information.
The Cellular Component DAG for the proteome T2-018T (UREA) Figure 4
The Cellular Component DAG for the proteome T2-018T (UREA). At a node filter setting of only 13, extracellular 
matrix proteins are highly evident. Thus, extracellular matrix proteins are soluble primarily in urea buffer.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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Complete Cellular Component DAGs for T2-048T (RIPA)
and T2-048T (Urea), T2-048N1 (RIPA) and T2-048N2
(Urea), and T2-029T1 (RIPA) and T2-029T2 (Urea), are
available as Additional Files 7, 8, 9, 10, 11 and 12, respec-
tively.
Molecular Function
Molecular Function annotations also contain elements
that reveal protein solubilization preferences of the RIPA
and urea buffers. Thus far, Structural Molecule Activity
(SMA) is the only functionality in the Molecular Function
annotation that contains nodes that directly relate to the
protein solubility preferences. In general, the SMA node of
the urea proteome contains a child node, Extracellular
Matrix Structural Constituent, which contains the
number of annotated protein sequences and an annota-
tion score for extracellular matrix proteins. The SMA
node of the RIPA proteome does not contain any descrip-
tors (at the given node filter settings) that suggest the pres-
ence of Extracellular Matrix Structural Constituent.
Thus, extracellular matrix proteins are observed nearly
exclusively in the urea fraction.
The Molecular Function DAGs for T2-018T (RIPA) and
T2-018T (UREA) (Figures 12 and 13, respectively) show
clearly that Extracellular Matrix Structural Constituents
are present only in the urea proteome. The RIPA and urea
Close-up views of the extracellular regions of T2-018T (UREA) Figure 5
Close-up views of the extracellular regions of T2-018T (UREA). clearly show that extracellular matrix proteins dis-
solve almost exclusively in urea buffer.
Expanded view of the extracellular region of the cellular  component DAG for the proteome T2-018T (UREA) Figure 6
Expanded view of the extracellular region of the cel-
lular component DAG for the proteome T2-018T 
(UREA). The node filter was reduced to 0 to obtain this 
complete display. Lowering the DAG node filter for the RIPA 
DAG did not produce appreciable change in the number of 
nodes displayed within the extracellular region.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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DAGs are drawn with node filter settings of 30 and 12,
respectively.
In Figure 14(A–B) are the cropped-out SMA nodes for T2-
018T (RIPA) and T2-018T (UREA), when the node filters
are set to 2 and 1, respectively. Further lowering of the
node filters did not produce significant differences in both
DAGs. Also shown in Figure 14(C–D), are the cropped-
out SMA nodes for T2-029T1 (RIPA) and  T2-029T2
(UREA) proteomes. Again, extracellular matrix proteins
are found nearly exclusively in the urea fractions.
The above trend is consistently maintained in Figure 15
(A-D) for T2-048T (RIPA) and T2-048T (UREA), and T2-
048N1 (RIPA) and T2-048N2 (UREA), respectively.
Detailed Molecular Function DAGs for T2-048T (RIPA)
and T2-048T (Urea), T2-048N1 (RIPA) and T2-048N2
(Urea), and T2-029T1 (RIPA) and T2-029T2 (Urea), are
available as Additional Files 13, 14, 15, 16, 17 and 18,
respectively.
Discussion
The solubility of proteins in RIPA and urea buffers
depends on several physicochemical factors, including the
characteristics of the proteins and properties of the RIPA
and urea buffers.
Physicochemical properties of the proteins that affect
their solubility include average charge, determined by the
relative numbers of Asp, Glu, Lys, and Arg residues, and
the content of turn-forming residues (Asn, Gly, Pro, and
Ser) [39]. Insoluble proteins tend to have more hydro-
phobic stretches longer than 20 amino acids residues,
lower glutamine content, fewer negatively charged resi-
dues, and higher percentages of aromatic amino acid resi-
dues than soluble ones [40]. Indeed, high contents of
negatively charged amino-acid residues and absence of
hydrophobic patches tend to improve protein solubility
[41]. Also, low percentage of aspartic acid, glutamic acid,
asparagines and glutamine residues increases the proba-
bility of a protein to be insoluble [41].
Solubility of proteins in lysis buffer also depends highly
on the composition and gross physicochemical properties
of the lysis buffer. These include [42,43]: the type of
buffer, the presence or absence of phosphate, pH, salts,
ampholytes, detergents, chaotropic agents, reducing
agents (dithiothreitol (DTT), dithioerythreitol (DTE), β-
mercaptoethanol, tributyl phosphine (TBP), tris-carboxy-
lethylphosphate (TCEP)).
Extraction of proteins from breast tumors for proteomic  analysis Figure 7
Extraction of proteins from breast tumors for pro-
teomic analysis. nuclear proteins (A), intracellular proteins 
(C) and protein complexes (D), are more soluble in RIPA 
buffer than in urea buffer RIPA, whereas membrane proteins 
(B) are slightly more soluble in urea buffer.
Extraction of proteins from breast tumors for proteomics Figure 8
Extraction of proteins from breast tumors for pro-
teomics. proteins of the extracellular region (A) and 
cytoskeleton (B) are more soluble in urea buffer than in 
RIPA, whereas for cytoplasmic (C) and mitochondrial (D) 
proteins, RIPA buffer is preferred.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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RIPA and UREA buffers fractionate breast cancer proteins 
primarily on the basis of molecular weights
RIPA buffer is a versatile and efficient lysis buffer suitable
for the recovery of most proteins, including whole cell,
nuclear, mitochondrial, membrane receptors, cytoskele-
tal-associated, and soluble proteins. However, as the data
in Figures 2 shows, there is a high molecular weight cut-
off (≥ 12% higher average molecular weight in urea than
RIPA) for a protein's solubility in RIPA buffer. Proteins
with molecular weights of around 100 kDa or higher may
not dissolve readily, unless they possess unique structural
features that enhance their solubility in RIPA buffer. Thus,
when a given protein group is subjected to RIPA buffer
extraction, the high molecular weight fraction may not
dissolve – they are recovered as the RIPA-insoluble frac-
tion that ultimately dissolve in urea buffer. This may
explain why such a high percentage of proteins are recov-
ered in the urea fraction after they have resisted solubility
Close-up views of the extracellular regions of the Cellular Component DAG of the proteomes T2-048T (RIPA) and T2-048T  (UREA) Figure 9
Close-up views of the extracellular regions of the Cellular Component DAG of the proteomes T2-048T (RIPA) 
and T2-048T (UREA). Extracellular matrix proteins and virions are observed almost entirely in urea fraction.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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in RIPA buffer (Figures 2D, especially Figures 2D (T2-029
(TUMOR)).
Interestingly, Ignatoski and co-workers [42] have also
demonstrated that different lysis buffers solubilized dif-
ferent subsets of cellular proteins (rather than entire pro-
teins), based primarily on the molecular weights. Neither
RIPA nor urea buffer was, however, used in this kinase
assay – they denature kinases. All buffers that they tested
were non-denaturing.
Nearly all extracellular matrix proteins are insoluble in 
RIPA buffer, but dissolve readily in urea buffer
Perhaps the most important finding in this work is that
nearly all extracellular matrix proteins (ECMs) are insolu-
ble in RIPA buffer, whereas they dissolve readily in urea
buffer. This may be due to ECMs having very high molec-
ular weights. Why, then, is RIPA buffer being used rou-
tinely to dissolve extracellular matrix proteins by
researchers, especially in cancer research? Indeed, RIPA
buffer does dissolve high molecular weight proteins, but
the recovery may be poor. The solubility of a protein is a
combination of many factors beyond the nature of the
lysis buffer. If, for example, the high molecular weight
protein has structural features that enhance its solubility
(high contents of negatively charged amino-acid residues
and absence of hydrophobic patches [41]), as discussed in
the introduction section, the protein would dissolve in
RIPA buffer. On the other, a smaller molecular weight
protein may surprisingly fail to dissolve in RIPA buffer, if
it aggregates or possesses structural features that hamper
its solubility. Some epigenetic, post-translation, or spon-
taneous structural changes can also impede a protein's
solubility in RIPA buffer. One example is tau, which
would normally be soluble in RIPA. But when it becomes
hyperphosphorylated, for example, by endogenously
overproduced Aβ protein in Alzheimer's disease, it would
resist solubility in RIPA buffer [44].
Selective Enrichments of Protein Groups by RIPA and Urea 
Buffers
Data in Figure 7A shows that nuclear proteins are some-
what more selectively enriched in RIPA buffer than in
urea, consistent with many standard molecular biology
laboratory practices: RIPA buffer is one of the recom-
mended (or one of the preferred) buffers for efficient
recovery of nuclear proteins [6,45,46].
Protein complexes (Figure 7D) are also slightly more con-
centrated in RIPA buffer than in urea. Protein complexes
tend to have high molecular weights, and although RIPA
buffer has poor solubility for high molecular weight pro-
teins, protein complexes are held together largely by non-
covalent bonds. Detailed Cellular Component DAGs
(DAGs not shown) indicate that protein complexes
referred to here include: immunoglobulin complex,
hemoglobin complex, fibrinogen complex, transcriptor
factor complex, DNA polymerase complex, DNA-directed
Close-up views of the extracellular regions of the Cellular Component DAG of the proteomes T2-048N (RIPA) and T2-048N  (UREA) Figure 10
Close-up views of the extracellular regions of the Cellular Component DAG of the proteomes T2-048N (RIPA) 
and T2-048N (UREA). Extracellular matrix proteins and virions are observed almost exclusively in urea fraction.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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RNA polymerase II holoenzyme, RNA polymerase com-
plex, nucleosome, myosin, laminin complex, membrane
attack complex, mediator complex, tubulin, MHC protein
complex and ribonucleocomplex.
Mitochondrial proteins also appear to be slightly more
favored by RIPA buffer than urea (Figure 8D). Again, RIPA
buffer is one of the recommended lysis buffers for the
recovery of mitochondrial proteins for Western blot [6].
On the other hand, urea buffer is clearly more efficient in
selectively enriching extracellular region and cytoskeletal
proteins (Figures 7A and 7B), in addition to extracellular
matrix proteins already discussed. Neither RIPA buffer nor
urea buffer is significantly preponderant in selective
enrichment of membrane, intracellular, or cytoplasmic
proteins (Figures 7B and 7C, and Figure 8C, respectively).
Limitations of RIPA and Urea Buffers
There is no single lysis buffer that would solubilize all
classes of proteins, however. Each buffer has its pros and
cons. Some of the known limitations of RIPA and urea
buffers are highlighted below.
RIPA buffer-induced post-lysis modulation of biochemical 
pathways
RIPA buffer has been shown to alter some biochemical
pathways, leading to experimental results that may be
spurious. Hence, the need to verify data by using other
lysis buffers. Two examples are provided herein.
In one example, DeSeau and co-workers [47] showed that
the level of pp60c-src kinase activity detected in immune
complex protein kinase assays can be substantially modu-
lated by RIPA buffer. They, thus, advise that comparing of
the results of pp60c-src in vitro protein kinase assays in
other cellular systems where only RIPA buffer lysis has
been used should be interpreted with caution. Specifi-
cally, they found that the in vitro protein kinase activity of
pp60c-src molecules derived from RIPA buffer lysates of
colon carcinoma cells was elevated five- to sevenfold
when compared with pp60c-src from the same cells lysed in
Close-up views of the extracellular regions of the Cellular Component DAG of the proteomes T2-029T (RIPA) and T2-029T  (UREA) Figure 11
Close-up views of the extracellular regions of the Cellular Component DAG of the proteomes T2-029T (RIPA) 
and T2-029T (UREA). Extracellular matrix proteins are observed almost exclusivly in urea fraction (right).Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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a buffer containing only Nonidet-P 40. Additionally, they
found that in RIPA buffer, the difference in specific activ-
ity of pp60c-src between normal colon mucosal cells and
colon carcinoma cells is about ten-to thirtyfold, whereas
with a lysis buffer containing only Nonidet-P 40 as a
detergent, the difference would be less than three- to four-
fold. Thus, if Nonidet-P 40 or other lysis buffers were not
used in an effort to validate data obtained in RIPA buffer,
the entire data on this work could have been in error.
In another example, abnormally high caspase-3 and -7
activity in stimulated human peripheral blood lym-
phocytes (PBLs) has been shown to be a spurious side
effect caused by RIPA buffer that was used to lyse the acti-
vated T-lymphocytes [48]. In contrast, when a lysis buffer
containing 2% SDS was used, the caspases remained in
their zymogen proforms, and no proteolytic processing of
caspase  substrates was detected. It was subsequently
determined that the release liberation of GraB or similar
proteases from cytotoxic granules during the lysis proce-
dure was responsible for artifactual activation of caspase-
3. RIPA may disrupt GraB-containing granules more effi-
ciently than 0.2% Nonidet P-40 or other lysis buffers used
[48].
Many protein groups are insoluble in urea buffer
Although urea buffer has proven very effective in dissolv-
ing extracellular matrix proteins and a wide range of other
protein groups, it nevertheless has limitations. In fact,
Granier [49] noted that many membrane proteins are
insoluble in urea, if extracted without heating. And, as
mentioned in the Background section above, heating urea
in the presence of proteins most likely would result in cov-
alent modifications of the protein by the hydrolysis prod-
ucts produced by heating urea (e.g. carbamylation of
proteins by isocyanate). Thus, urea does not possess uni-
versal solubility for all membrane proteins. Ames and
Nikaido [50] solubilized membrane proteins of salmonella
typhimurium with hot SDS when even the most powerful
O'Farrell's buffer (urea buffer) [51] failed to dissolve the
membrane proteins.
A cell surface proteoglycan, with a molecular weight of
450 kDa, was also found to be very insoluble in urea
buffer [16].
In general, many proteins that have proven insoluble in
urea buffer are shown to be human lens proteins [52,53],
especially cataractous proteins [52-54]. Weber and
McFadden described a heterogenous set of urea-insoluble
proteins in dividing PC12 pheochromocytoma cells. They
found that about 5% of the total cellular proteins synthe-
sized in exponentially dividing PC12 pheochromocytoma
cells remained insoluble even in 6 M urea [55].
A major factor that decreases the solubility of proteins in
urea is the formation of disulfide cross-bridges, which can
be acquired by a protein through aerobic oxidation of
Molecular Function DAG for the proteome T2-018T (RIPA) Figure 12
Molecular Function DAG for the proteome T2-018T (RIPA). Extracellular matrix structural constituents are not seen, 
even at a node filter setting of 12.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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thiol groups. Even a small molecular weight protein could
become very insoluble in urea upon formation of disul-
phide bridges. This was the case with a 42 kDa Rec12
(Spo11) meiotic recombinase of fission yeast (Rec12 pro-
tein) [56] that was expressed in E. coli. Rec12 protein
resisted solubility in 6 M urea, but was ultimately
extracted with 6 M Guanidine hydrochloride [56]. Subse-
quent analyses showed that it has four disulfide bridges
that impeded its solubility in urea. Human eye lens pro-
teins acquire disulfide cross-bridges by exposure to hyper-
baric oxygen (Reviewed in Ref. [52]). The eye lens proteins
then become opaque, cataractous and resist solubility in
urea buffer [52].
Another example is the human centrosomal protein
which exists as a doublet of 62/64 kDa and is insoluble in
even 8 M urea (a condition that would dissolve most
known centrosomal proteins) [57].
Preferential solubilization of extracellular matrix proteins 
in urea lysis buffer: variables
Despite differences in the breast tumors analyzed in this
work (Table 1), a common feature remains the preferen-
tial solubilization of extracellular matrix proteins in urea
lysis buffer. Differences include (Table 1): breast location
(right breast, left breast, left breast, bilateral); Diagnosis
(Infiltrating Ductal Carcinoma, Infiltrating Ductal Carci-
noma, Adenocarcinoma), Stage of the tumor (IV
T4N0M0, IIB T2N1M0, IIB T4N1M0), Grade of the tumor
(II, I, I, III), Patient Age (yrs: 75, 39, 39, 47), and gross
findings).
Conclusion
This work shows that most extracellular matrix proteins
(ECM) in the breast tumors and matched normal tissues
in this work are dissolved in the urea buffer fraction: they
are mostly insoluble in RIPA buffer. Because ECMs are
highly important in cancer, including tumor develop-
ment, progression, adhesion and metastasis, important
information may be missed in cancer research if they are
not efficiently extracted by RIPA buffer.
This work also shows that RIPA and urea lysis buffers frac-
tionate tissue proteins primarily on the basis of molecular
weights. The average molecular weight of proteins that
dissolve exclusively in urea buffer is higher (up to 60%)
than in RIPA.
Protein complexes, nuclear, mitochondrial, cytoplasmic
and intracellular proteins are more soluble in RIPA buffer
than in urea, whereas membrane, cytoskeletal and extra-
cellular region proteins are more soluble in urea buffer.
Molecular Function DAG for the proteome T2-018T (UREA) Figure 13
Molecular Function DAG for the proteome T2-018T (UREA). The Structural Molecule Activity of the urea proteome 
contains 13 extracellular matrix structural constituents. None is observed in the RIPA buffer fraction DAG of Figure 12 shown 
above. Thus, extracellular matrix proteins are soluble primarily in urea buffer.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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For proteomic analyses of breast tumors, and other solid
tumors, a two-step extraction process is herein recom-
mended. First, the tumor should be subjected to RIPA pro-
tein extraction. Second, the insoluble matter left after
RIPA extraction should be probed for residual protein
content by extracting with the urea-based buffer described
in this work.
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Close-up views of the Structural Molecule Activity node of T2-018T (RIPA), Panel A, compared to the SMA of T2-018T  (UREA), Panel B Figure 14
Close-up views of the Structural Molecule Activity node of T2-018T (RIPA), Panel A, compared to the SMA of 
T2-018T (UREA), Panel B. The SMA of T2-018T (UREA) contains a node corresponding to extracellular matrix structural 
constituents, whereas no ECM constituents are seen in the SMA of T2-018T (RIPA). Panels C and D compare the SMA nodes 
of T2-029T (RIPA) and T2-029T (UREA), respectively, wherein it is seen that no extracellular matrix structural constituents 
are present in T2-029T (RIPA).Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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Close-up views of the Structural Molecule Activity of the Molecular Function DAG of the proteomes T2-048T (RIPA) and T2- 048T (UREA), and T2-048N (RIPA) and T2-048N (UREA) Figure 15
Close-up views of the Structural Molecule Activity of the Molecular Function DAG of the proteomes T2-048T 
(RIPA) and T2-048T (UREA), and T2-048N (RIPA) and T2-048N (UREA). Extracellular matrix structural constitu-
ents are observed nearly exclusively in the urea fractions, Panels B and D.Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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Additional material
Additional file 1
BLAST Table for discoidin domain receptor 1 (DDR1). BLAST Table 
for discoidin domain receptor 1 (gi|68533097|dbj|BAE06103.1|/894). 
For each protein input query, the BLASTmachine generates a BLAST 
Table [34]. The table shows parameters of the BLAST search, including  
Sequences producing significant alignments,  Gene Name,  Acces-
sion number,  e-Value,  align-length,  positives,  similarity %,  hsp 
and  mapping (Ontologies found), for each of the 40 hits requested.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S1.xls]
Additional file 2
MudPIT Mass Spectra of the breast tumor T2-018 TUMOR. The set of 
12 MudPIT mass spectra of the RIPA-soluble fraction are shown at left, 
whereas those for the urea-soluble fraction are shown at right. A typical 
MudPIT experiment consists of a 12-cycle run in which a 60-minute 
nano-LC gradient is run for each of: 1. 1D_2 μL sample; 2. 2D_10 μL 
sample; 3. 2D_0 mM NH4COO-; 4. 2D_25 mM NH4COO-; 5. 2D_50 
mM NH4COO-; 6. 2D_75 mM NH4COO-; 7. 2D_100 mM NH4COO-
; 8. 2D_150 mM NH4COO-; 9. 2D_200 mM NH4COO-; 10. 2D_250 
mM NH4COO-; 11. 2D_300 mM NH4COO-, and 12. 2D_500 mM 
NH4COO-. NH4COO- is ammonium formate.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S2.tiff]
Additional file 3
MudPIT Mass Spectra of the breast tumor T2-048 TUMOR. MudPIT 
Mass Spectra of the breast tumor T2-048 TUMOR. Spectra of RIPA-sol-
uble fraction are shown at left, whereas those for the urea-soluble fraction 
are shown at right.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S3.tiff]
Additional file 4
MudPIT Mass Spectra of the matched normal breast tissue T2-048 
NORMAL. The set of 12 MudPIT mass spectra of the RIPA-soluble frac-
tion are shown at left, whereas those for the urea-soluble fraction are 
shown at right.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S4.tiff]
Additional file 5
MudPIT Mass Spectra of the bilateral breast tumor T2-029 TUMOR. 
The set of 12 MudPIT mass spectra of the RIPA-soluble fraction are shown 
at left, whereas those for the urea-soluble fraction are shown at right.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S5.tiff]
Additional file 6
Expanded view of the extracellular region of the Cellular Component 
DAG for the bilateral proteome T2-029T (UREA). The node filter was 
reduced to 0 to obtain this complete display. In contrast, lowering the 
DAG node filter for the RIPA DAG counterpart did not produce appreci-
able change in the number of nodes displayed within the extracellular 
region.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S6.png]
Additional file 7
Cellular Component DAG for the proteome T2-048T (RIPA). Extra-
cellular matrix proteins are not seen, even when the node filter is lowered 
to 10.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S7.png]
Additional file 8
Cellular Component DAG for the proteome T2-048T (UREA). At a 
node filter setting of 16, there are 31 extracellular matrix proteins. Thus, 
extracellular matrix proteins are soluble almost exclusively in urea buffer. 
None is seen in the RIPA buffer fraction of this proteome (Additional File 
7).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S8.png]
Additional file 9
Cellular Component DAG of the matched normal proteome T2-048N 
(RIPA). Extracellular matrix proteins are not seen, even at a node filter 
setting of 14.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S9.png]
Additional file 10
Cellular Component DAG of the matched normal proteome T2-048N 
(UREA). Twenty-nine extracellular matrix proteins are present in this 
urea buffer fraction of T2-048N, even when the DAG is displayed with a 
node filter setting of just 5 (cf. Node filter is 14 in Additional File 9 
above); no extracellular matrix proteins are present in the RIPA buffer 
fraction of this proteome, shown in Additional File 9 above.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S10.png]
Additional file 11
Cellular Component DAG of the bilateral Adenocarcinoma proteome 
T2-029T (RIPA). Extracellular matrix proteins are not seen, even at a 
node filter setting of 12.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1477-
5956-6-30-S11.png]Proteome Science 2008, 6:30 http://www.proteomesci.com/content/6/1/30
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